Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2019 · 10-Q
Revenue$6.27M$6.27M+14.0% vs Q2 2018 Net Income-$5.30M-$5.30MN/M vs Q2 2018 EPS Diluted-$1.39-$1.39N/M vs Q2 2018 Gross Profit$3,239,000−0.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,825,000N/M Free Cash Flowderived-$4,861,000N/M Margins · derivedGross margin51.7%−7.5 pt vs Q2 2018
Operating margin-85.3%−50.8 pt vs Q2 2018
Net margin-84.6%−48.2 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 13, 2019 · 44 d after period end